FLVCR2-AS1: A Potential Drug Target and Biomarker (G102724153)

Target Name: FLVCR2-AS1

NCBI ID: G102724153

FLVCR2-AS1

Other Name(s): FLVCR2 antisense RNA 1

FLVCR2-AS1: A Potential Drug Target and Biomarker

FLVCR2-AS1, also known as FLVCR2 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has led to a growing interest in the field of biotechnology and medicine.

FLVCR2-AS1 is a small non-coding RNA molecule that is expressed in various tissues and cells of the body. Its primary function is to act as an antisense RNA, meaning it binds to a specific mRNA and prevents it from being translated into protein. This process is known as post-transcriptional modification (PTM) and is a common mechanism used by cells to regulate gene expression.

FLVCR2-AS1 has been shown to play a role in several diseases, including cancer. For example, studies have shown that FLVCR2-AS1 is downregulated in various types of cancer, and that increasing its expression can inhibit the growth of cancer cells. This suggests that FLVCR2-AS1 may be a useful drug or biomarker for cancer treatment.

In addition to its potential as a cancer drug, FLVCR2-AS1 has also been shown to be a potential biomarker for several other diseases. For example, it has been shown to be downregulated in individuals with Alzheimer's disease, and that increasing its expression may be a useful diagnostic tool for this disease. Additionally, FLVCR2-AS1 has been shown to be downregulated in individuals with mental infarction, and that increasing its expression may be a useful biomarker for this disease.

FLVCR2-AS1's unique structure and function also make it an attractive target for research into neurodegenerative diseases. For example, studies have shown that FLVCR2-AS1 is downregulated in individuals with Alzheimer's disease, and that increasing its expression may be a useful drug or biomarker for this disease.

In conclusion, FLVCR2-AS1 is a promising drug target and biomarker for several diseases, including cancer, Alzheimer's disease, and mental infarction. Its unique structure and function make it an attractive target for research, and its potential as a drug or biomarker has led to a growing interest in the field of biotechnology and medicine. Further studies are needed to fully understand its potential and to develop effective treatments for its associated diseases.

Protein Name: FLVCR2 Antisense RNA 1

The "FLVCR2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLVCR2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets